Investors who might be interested in pharmaceutical stocks could consider having a look at the AcelRx Pharmaceuticals (NASDAQ: ACRX) stock.
It has been one of the better performers in the sector this year and clocked gains of as big as 75% so far. Considering the magnitude of the gains, it might be a good idea to take a closer look. While there has been no recent development with regards to AcelRx, last month the company had a setback after it received a warning letter from the FDA with regards to the promotional claims about its product Dsuvia.
The letter noted that the banner, display, and promotional communications related to the product from AcelRx were ‘false or misleading. The product had been approved by the regulatory agency back in November 2020 for adults who suffer from acute pain. At the time, the company had been asked to send in a written response to the warning letter.
Writing for business and finance publishers has become his passion over the last decades after he completed a master’s degree in Financial Management. Sharing some opinions and forecasts to thousands of readers is a routine job for him but he never promises to invest in one stock.